Early-onset preeclampsia is a severe placental disorder driven primarily by impaired uteroplacental perfusion and early placental ischemia. Increasing evidence identifies HIF-1α–mediated hypoxic signaling as a central regulator linking placental ischemia to downstream molecular and clinical manifestations. During early gestation, tightly controlled hypoxia guides normal trophoblast differentiation and vascular remodeling. Persistent or excessive hypoxia stabilizes HIF-1α, leading to defective trophoblast invasion, impaired spiral artery remodeling, and progressive placental ischemia. Sustained HIF-1α activation drives mitochondrial dysfunction and oxidative stress, amplifying placental injury. At the transcriptional level, HIF-1α promotes antiangiogenic programs, including sFlt-1 upregulation, resulting in systemic angiogenic imbalance and maternal endothelial dysfunction. These processes explain the severity, early onset, and rapid progression of the maternal syndrome. This review integrates current evidence on hypoxia sensing, trophoblast biology, mitochondrial stress, and angiogenic dysregulation to define HIF-1α as a unifying mechanistic hub in early-onset preeclampsia. Understanding HIF-1α–centered signaling provides a framework for improved biomarker development and targeted therapeutic strategies. Failure of trophoblast invasion and spiral artery remodeling sustains placental ischemia and hypoxia–reoxygenation stress in preeclampsia. HIF-1α–driven placental ischemic signaling in early-onset preeclampsia based on inflammatory signaling, metabolic reprogramming, and epigenetic regulation.
You et al. (Sun,) studied this question.